(i)
APHRIA AND TILRAY COMBINE TO CREATE
LARGEST GLOBAL CANNABIS COMPANY WITH PRO FORMA REVENUE OF
C$874 MILLION (US$685 MILLION)
Complementary, Scalable Medical and Adult-Use Cannabis Businesses Strengthen Leadership Position in
Canada; Expands U.S. and International Reach through World-Class Cultivation, Manufacturing, Diversified Product Portfolio and Distribution Footprint
Robust Supply Chain and Operational Efficiencies Expected to Generate Approximately C$100 Million of
Pre-Tax Annual Cost Synergies
Aphria and Tilray to Host a Conference Call and Webcast at
8:30 a.m. Eastern Time
Leamington, Ontario and Nanaimo, British Columbia December 16, 2020 Aphria Inc. (Aphria)
(TSX: APHA and Nasdaq: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, and Tilray, Inc. (Tilray) (Nasdaq: TLRY), a global pioneer
in cannabis research, cultivation, production and distribution, today announced that they have entered into a definitive agreement (the Agreement) to combine their businesses and create the worlds largest global cannabis
company (the Combined Company) based on pro forma revenue1. The deal is pursuant to a plan of arrangement (the Arrangement) under the Business
Corporations Act (Ontario), and the implied pro forma equity value of the Combined Company is approximately C$5.0 billion (US$3.9 billion), based on the share price of Aphria and Tilray at the close of market on December 15, 2020.
Following the completion of the Arrangement, the Combined Company will have principal offices in the United States (New York and Seattle), Canada (Toronto, Leamington and Vancouver Island), Portugal and Germany, and it will operate under the
Tilray corporate name with shares trading on NASDAQ under ticker symbol TLRY.
The Combined Company, supported by low-cost, state-of-the-art cultivation, processing, and manufacturing facilities, will have a
complete portfolio of branded Cannabis 2.0 products in Canada. Internationally, the Combined Company will be well-positioned to pursue growth opportunities with Aphrias medical cannabis and distribution footprint in Germany, and Tilrays
European Union Good Manufacturing Practices (EU-GMP) low-cost cannabis production facility in Portugal, which has export capabilities and tariff-free
access to the European Union (EU) to meet increasing global demand for medical cannabis. In the United States, the Combined Company will have a strong consumer packaged goods presence and infrastructure with two
strategic pillars, including SweetWater Brewing Company (SweetWater), a cannabis lifestyle branded craft brewer, and Manitoba Harvest, a
leading hemp food manufacturer and a pioneer in branded CBD and wellness products. The Combined Company is expected to have a strong, flexible balance sheet, cash balance and access to capital giving it the ability to accelerate growth and deliver
attractive returns for stockholders.
Under the terms of the Arrangement, the shareholders of Aphria (the Aphria Shareholders) will
receive 0.8381 shares (the Exchange Ratio) of Tilray for each Aphria common share (each, an Aphria Share), while holders of Tilray shares (the Tilray Stockholders) will continue to hold
their Tilray shares (the Tilray Shares) with no adjustment to their holdings. Upon the completion of the Arrangement, Aphria Shareholders will own approximately 62 percent of the outstanding Tilray Shares on a fully diluted
basis, resulting in a reverse acquisition of Tilray, representing a premium of 23 percent based on the share price at market close on December 15, 2020 to Tilray shareholders. On a pro forma basis for the last twelve months reported by
each company, the Combined Company would have had revenue of C$874 million (US$685 million).
1
|
Based on the most recently reported quarterly financial statements for Aphria and Tilray.
|